

From: HarrisMartin's Hip & Knee Implant Litigation Publication

Date: November 26, 2014

www.harrismartin.com

## The Cobalt and Chromium Conundrum: A Survey of Hip Implant Litigation, Part II

For Part I of this commentary, please [Click Here](#).

In re Zimmer Durom Hip Cup Products Liability Litigation – MDL 2158

Zimmer's Durom Acetabular Cup (Durom Cup) received FDA clearance for marketing via the 510(k) process and entered the U.S. market in 2006.<sup>86</sup> After only two years on the market, Zimmer suspended its sales because of mounting complaints from patients and doctors concerning the component's propensity for premature failure.<sup>87</sup> However, the company did not issue a recall and put the device back on the market a few months later.<sup>88</sup>

While Zimmer initially indicated in a follow-up study that up to 5.7 percent of implants would need to be replaced in the U.S. and Europe, alternative investigations have suggested a higher rate of failure. Plaintiffs have contended in lawsuits that the actual failure rate is upwards of 24 percent. Zimmer permanently discontinued sales of the device in 2010. The Durom Cup was implanted in over 12,000 patients in the United States since it was first sold on the U.S. market in 2006.

Lawsuits concerning Zimmer's Durom Acetabular Cup component were the first MoM-related cases to receive MDL treatment. In June 2010, the JPML transferred federal Zimmer hip cases to the District of New Jersey for pretrial coordination.<sup>89</sup> As seen in other MoM litigation, the federal Zimmer cases in the MDL are being pursued in coordination with state court actions, most notably with state court cases pending in New Jersey.

The Zimmer MDL is presided over by Judges Susan D. Wigenton and Madeline Arleo. Since the MDL's inception, Zimmer has settled with numerous plaintiffs on an individual basis, mostly through court ordered mediation. To date, Zimmer has allocated approximately \$400 million for settlement purposes. In its most recent annual report, Zimmer stated that it expects to spend an additional \$200 million to settle pending lawsuits by the end of 2014.<sup>90</sup>

Currently, parties in the MDL are feverishly attempting to complete discovery in advance of the first two bellwether trials scheduled to take place in March and May 2015.<sup>91</sup> Discovery disputes have risen concerning the sufficiency of fact sheets, potential spoliation on the part of Zimmer, depositions of corporate reps and experts, and the admissibility of expert testimony.

Notably, Zimmer announced in April 2014 that it was acquiring Biomet.<sup>92</sup> When the sale is completed in early 2015, it will make Zimmer the number two manufacturer of orthopedics in the country.

### The Future of MoM Hip Implant Litigation

It appears that litigation concerning metal-on-metal hip implant devices will persist – certainly, at least, for the

foreseeable future. Viewed in relation to more traditional mass torts involving medical devices, the current MoM litigation is relatively young. New cases continue to be filed and thousands of cases remain unresolved. Moreover, the cases that have been filed represent only a fraction of the potential cases involving the devices currently at issue. For instance, out of the aforementioned devices that have been recalled, only a small percentage of implanted patients have filed claims. And it is possible for complications associated with MoM implants to take several years to develop.

---

**“The use of MoM implants has decreased dramatically since their distribution peak in the mid-2000s. Then, almost one in every three THA implants utilized a MoM configuration. Today, MoM devices account for less than 3 percent of hip implant units sold in the United States.”**

---

Of course, this is not to say that MoM litigation will go on in perpetuity. The use of MoM implants has decreased dramatically since their distribution peak in the mid-2000s. Then, almost one in every three THA implants utilized a MoM configuration. Today, MoM devices account for less than 3 percent of hip implant units sold in the United States. Further, should the FDA’s new rule become finalized and subject the majority of new MoM implant technology to the PMA process, subsequent litigation concerning new MoM products may be barred based on preemption grounds.

Yet, as the aforementioned verdicts and settlements suggest, these cases presently have substantial value. Therefore, they are attractive cases to pursue. But these cases also present the possibility of requiring considerable investment in terms of both time and expense for their successful prosecution. Plaintiff practitioners may find it wise to note some of the potential limitations derived from the existing MoM litigation in assessing each case. The specific device at issue and the potential client’s medical history are of obvious importance. And, whether the potential client has had a revision procedure performed, or has been diagnosed or is suspected of having related complications, are questions that must be asked. Forum selection and the propensity for merits-based and jurisdictional defenses are also key considerations. For example, a client’s past revision surgery or heightened metal-level report may trigger a statute of limitations defense if the revision surgery or metal-levels report occurred outside of the time constraints for the particular cause(s) of action asserted. This is of particular concern for causes of action based on state law.<sup>93</sup>

The next few years of MoM litigation should provide significant guidance on all of these issues. It will be very interesting to see how future developments unfold.

#### Endnotes

<sup>1</sup> Clark, I.C., et al. (2005). Current Concepts of Metal-on-Metal Resurfacing. *Orthopedic Clinics of North America*, 36(2), 143-62.

<sup>2</sup> *Id.*

<sup>3</sup> FDA Executive Summary Memorandum, *Metal-on-Metal Hip Implant Systems: Prepared for June 27-28, 2012 Meeting of the Orthopaedic and Rehabilitation Devices Advisory Panel (June 27, 2012)* (“FDA Executive Summary Memo”).

<sup>4</sup> Griffin, J., et al. (2012). Management of Failed Metal-on-Metal Total Hip Arthroplasty. *World Journal of Orthopedics* 3(6), 70-74.

<sup>5</sup> FDA Executive Summary Memo at 6.

<sup>6</sup> Triclot, P. (2011). Metal on Metal: History, State of the Art (2010). *International Orthopaedics* 35(2), 201-06.

<sup>7</sup> August, A.C., et al. (1986). The McKee-Farrar Hip Arthroplasty: A Long-Term Study. *Journal of Bone and Joint Surgery B* 68(4), 520-27. Dobbs, H.S. (1980). Survivorship of Total Hip Replacements. *Journal of Bone and Joint Surgery B* 62(2), 168-73. Shimmin, A., et al. (2008). Metal-on-Metal Hip Resurfacing Arthroplasty. *Journal of Bone and Joint Surgery A* 90(3), 637-54.

<sup>8</sup> Benson, M.K., et al. (1975). Metal Sensitivity in Patients with Joint Replacement Arthroplasties. *British Medical Journal* 4(5993), 374-75. Evans, E.M., et al. (1974). Metal Sensitivity as a Cause of Bone Necrosis and Loosening of the Prosthesis in Total Joint Replacement. *Journal of Bone & Joint Surgery B* 56(4), 626-42.

<sup>9</sup> Weegen, W. van der (2014). Metal-on-Metal Hip Arthroplasty: Local Tissue Reactions and Clinical Outcome, Geldrop, (Netherlands). Dumbleton, J.H., & Manley, M.T. (2005). Metal-on-Metal Total Hip Replacement: What Does the Literature Say? *Journal of Arthroplasty* 20(2), 174-88.

<sup>10</sup> Pace, T.B., et al. (2013). Metal on Metal Hip Retrieval Analysis: A Case Report. *Case Reports in Orthopedics* 2013.

<sup>11</sup> EU Report at 6. Abu-Amer, Y., et al. (2007). Aseptic Loosening of Total Joint Replacements: Mechanisms Underlying Osteolysis and Potential Therapies. *Arthritis Research & Therapy* 9(1 Supp.), S6.

<sup>12</sup> Griffin, J.W., et al. (2012). Management of Failed Metal-on-Metal Total Hip Arthroplasty. *World Journal of Orthopedics* 3(6), 70-74. Harris, W.H. (2004). Conquest of a Worldwide Human Disease: Particle-Induced Periprosthetic Osteolysis. *Clinical Orthopaedics and Related Research* 429, 39-42.

<sup>13</sup> EU Report at 6. Harris, W.H. (2004). Conquest of a Worldwide Human Disease: Particle-Induced Periprosthetic Osteolysis. *Clinical Orthopaedics and Related Research* 429, 39-42.

<sup>14</sup> Macpherson, G. & Breusch, S. (2011). Metal-on-Metal Hip Resurfacing: A Critical Review. *Archives of Orthopaedic and Trauma Surgery* 131, 101-110.

<sup>15</sup> Weber, B.G. (1996). Experience with the Metasul Total Hip Bearing System. *Clinical Orthopaedics & Related Research* 1996(329 Supp.), S69-77. Weber, B.G., et al. (1993). Total Hip Joint Replacement using a CoCrMo Metal-Metal Sliding Pairing. *Journal of the Japanese Orthopaedic Association* 67, 391-98.

<sup>16</sup> Witten, Celia (Aug. 3, 1999) Inter-Op Metasul Acetabular System Application and Approval (available at [http://www.accessdata.fda.gov/cdrh\\_docs/pdf/k974728.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf/k974728.pdf))

<sup>17</sup> Zuckerman, D.M., et al. (2011). Medical Device Recalls and the FDA Approval Process. *JAMA Internal Medicine* 171(11), 1006-11.

<sup>18</sup>Id.

<sup>19</sup> Proposed Rule FDA-2011-N-0661-001, Federal Register 78(13), 4094 (Jan. 18, 2013) (available at

<sup>20</sup> August, A.C., et al. (1986). The McKee-Farrar Hip Arthroplasty: A Long-Term Study. *Journal of Bone and Joint Surgery B* 68(4), 520-27. Dobbs, H.S. (1980). Survivorship of Total Hip Replacements. *Journal of Bone and Joint Surgery B* 62(2), 168-73. Shimmin, A., et al. (2008). Metal-on-Metal Hip Resurfacing Arthroplasty. *Journal of Bone and Joint Surgery A* 90(3), 637-54. Benson, M.K., et al. (1975). Metal Sensitivity in Patients with Joint Replacement Arthroplasties. *British Medical Journal* 4(5993), 374-75. Evans, E.M., et al. (1974). Metal Sensitivity as a Cause of Bone Necrosis and Loosening of the Prosthesis in Total Joint Replacement. *Journal of Bone & Joint Surgery B* 56(4), 626-42. Schmalzried, T.P., et al. (1996). Long Duration Metal-on-Metal Total Hip Arthroplasties with Low Wear of the Articulating Surfaces. *Journal of Arthroplasty* 11(3), 322-31. Willert, H.G. & Buchhorn, G.H. (1999). Retrieval Studies on Classic Cemented Metal-on-Metal Hip Endoprostheses. *Metasul: a Metal-on-Metal Bearing*, Bern (Switzerland): Hans Huber. Dumbleton, J.H., & Manley, M.T. (2005). Metal-on-Metal Total Hip Replacement: What Does the Literature Say? *Journal of Arthroplasty* 20(2), 174-88. Howie, D.W. (1990). Tissue Response in Relation to Type of Wear Particles around Failed Hip Arthroplasties. *Journal of Arthroplasty* 5(4), 337-48.

<sup>21</sup>Id. Dorr, L.D., et al. (2000). Total Hip Arthroplasty with the use of Metasul metal-on-metal articulation. *Journal of Bone & Joint Surgery [Am]* 82A, 789.

<sup>22</sup> Willert, H.G., et al. (2005). Metal-on-Metal Hypersensitivity in Patients with Artificial Hip Joints: a Clinical and Histomorphological Study. *Journal of Bone & Joint Surgery [Am]* 87A, 28. Pandit H., et al. (2008). Pseudotumours associated with Metal-on-Metal Hip Resurfacings. *Journal of Joint & Bone Surgery [Br]* 90B, 487. Wiley, K.F., et al. (2013). Incidence of Pseudotumor and Acute Lymphocytic Vasculitis Associated Lesion (ALVAL) Reactions in Metal-On-Metal Hip Articulations: A Meta-Analysis. *Journal of Arthroplasty* 28(7), 1238-45. Kawakita, K., et al. (2013). Leg Edema Due to a Mass in the Pelvis after a Large-Diameter Metal-on-Metal Total Hip Arthroplasty. *Journal of Arthroplasty* 28(1), 197.e1-4. Liddle, A.D., et al. (2013). Revision of Metal-on-Metal Hip Arthroplasty in a Tertiary Center: a Prospective Study of 39 Hips with Between 1 and 4 Years of Follow-Up. *Acta Orthopaedica* 84(3), 237-45. Memon, A.R., (2013). Inflammatory Pseudotumor Causing Deep Vein Thrombosis after Metal-on-Metal Hip Resurfacing Arthroplasty. *Journal of Arthroplasty* 28(1), 197.e9-12.

<sup>23</sup>Id.

<sup>24</sup> Witten, C.M., Letter re 510(k) Approval for Biomet M2a Acetabular System (July 2, 2001); Witten, C.M., Letter re 510(k) Approval for Biomet M2a Magnum System (July 28, 2004) (both available at <http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDRH/CDRHFOIAElectronicReadingRoom/UCM264699.pdf>)

<sup>25</sup>In re Biomet M2a Magnum Hip Implant Products Liability Litigation, Case MDL No. 2391, Doc. 124 (J.P.M.L. Oct. 2, 2012).

<sup>26</sup>In Re Biomet M2A Magnum Hip Implant Products Liability Litigation, Case No. 3:12-md-2391-RLM-CAN (N.D. Ind.); (<http://www.innd.uscourts.gov/millermld2391.asp>)

<sup>27</sup>Id.

<sup>28</sup>In Re Biomet M2A Magnum Hip Implant Products Liability Litigation, Case No. 3:12-md-2391-RLM-CAN, Doc. 1118 (N.D. Ind. Dec. 10, 2013).

<sup>29</sup>In Re Biomet M2A Magnum Hip Implant Products Liability Litigation, Case No. 3:12-md-2391-RLM-CAN, Doc. 1317-1 (N.D. Ind. Jan. 31, 2014).

<sup>30</sup>In Re Biomet M2A Magnum Hip Implant Products Liability Litigation , Case No. 3:12-md-2391-RLM-CAN, Doc. 2758 (N.D. Ind. Sept. 19, 2014).

<sup>31</sup>In Re Biomet M2A Magnum Hip Implant Products Liability Litigation , Case No. 3:12-md-2391-RLM-CAN, Doc. 2756 (N.D. Ind. Sept. 18, 2014).

<sup>32</sup>In Re Biomet M2A Magnum Hip Implant Products Liability Litigation , Case No. 3:12-md-2391-RLM-CAN, Doc. 2773 (N.D. Ind. Oct. 20, 2014).

<sup>33</sup> Melkerson, M.N., Letter re 510(k) Approval for DePuy ASR Acetabular Cup System (Aug. 5, 2005) (available at [http://www.accessdata.fda.gov/cdrh\\_docs/pdf4/KO40627.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf4/KO40627.pdf))

<sup>34</sup> DePuy ASR Recall Notice (Aug. 24, 2010) (available at <http://www.depuy.com/sites/default/files/DPYUS1percent20Recallpercent20Notice.pdf>)

<sup>35</sup>Id.

<sup>36</sup> Eisner, W. (2012). Metal-on-Metal Hips: FDA Panel Offers Recommendations. *Orthopedics This Week* 8(22), 7-11.

<sup>37</sup>In re DePuy Orthopaedics, Inc., ASR Hip Implant Products Liability Litig. , Case No. 1:10-md-02197-DAK, Doc. 1 (N.D. Ohio Dec. 7, 2010) (<http://www.ohnd.uscourts.gov/home/clerk-s-office-and-court-records/multidistrict-litigation-cases/mdl-2197/>)

<sup>38</sup>Kransky v. DePuy Orthopaedics, Inc. et al. , Case No. BC-456086, Cal. Sup. Ct. (Los Angeles).

<sup>39</sup>Strum v. DePuy Orthopaedics, Inc., et al. , Case No. 2011-L-9352, Cook County Cir. Ct. (Chicago).

<sup>40</sup>Rundle, et al. v. DePuy Orthopaedics, Inc., et al. , Case No. A-11-636272-C, Dist. Ct. of Nevada (Clark County).

<sup>41</sup> A website for the ASR settlement has been created. Documents and other information may be found at: <https://www.usarhipsettlement.com/Home.aspx>

<sup>42</sup> DePuy ASR Settlement Agreement (Nov. 19, 2013) (available at [https://www.usarhipsettlement.com/Un-Secure/Docs/FINAL\\_ASR\\_SETTLEMENT.pdf](https://www.usarhipsettlement.com/Un-Secure/Docs/FINAL_ASR_SETTLEMENT.pdf))

<sup>43</sup>In re DePuy Orthopaedics, Inc., ASR Hip Implant Products Liability Litig. , Case No. 1:10-md-02197-DAK, Doc. 720 (N.D. Ohio June 27, 2014)

<sup>44</sup>In re DePuy Orthopaedics, Inc., ASR Hip Implant Products Liability Litig. , Case No. 1:10-md-02197-DAK, Doc. 749 (N.D. Ohio July 16, 2014).

<sup>45</sup>In re DePuy Orthopaedics, Inc., ASR Hip Implant Products Liability Litig. , Case No. 1:10-md-02197-DAK, Doc. 795 (N.D. Ohio August 14, 2014).

<sup>46</sup>In re DePuy Orthopaedics, Inc., ASR Hip Implant Products Liability Litig. , Case No. 1:10-md-02197-DAK, Doc. 836 (N.D. Ohio October 30, 2014).

<sup>47</sup>In re DePuy Orthopaedics, Inc., ASR Hip Implant Products Liability Litig. , Case No. 1:10-md-02197-DAK, Doc. 838 (N.D. Ohio October 31, 2014).

<sup>48</sup>Witten, C.M., Letter re 510(k) Approval for Pinnacle Metal-on-Metal Acetabular Cup Liners (Oct. 13, 2000) (available at [http://www.accessdata.fda.gov/cdrh\\_docs/pdf/k002883.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf/k002883.pdf)).

<sup>49</sup>DePuy Orthopaedics, Inc. (2013). Statement on Discontinuation of ULTAMET Metal-on-Metal and COMPLETE Ceramic-on-Metal Hip System [Press Release] (available at <http://www.depuy.com/about-depuy/news-and-press/detail?tid=21&year=2013&page=7>)

<sup>50</sup>Id.

<sup>51</sup>In re DePuy Orthopaedics, Inc., Pinnacle Hip Implant Products Liability Litig. , Case No. 3:11-md-02244-K, Doc. 1 (N.D. Tex. May 24, 2011) (<http://www.txnd.uscourts.gov/judges/MDL/depuy.html>)

<sup>52</sup>In re DePuy Orthopaedics, Inc., Pinnacle Hip Implant Products Liability Litig. , Case No. 3:11-md-02244-K, Doc. 92 (N.D. Tex. July 18, 2014).

<sup>53</sup>In re DePuy Orthopaedics, Inc., Pinnacle Hip Implant Products Liability Litig. , Case No. 3:11-md-02244-K, Doc. 91 (N.D. Tex. July 18, 2014); Doc. 140 (N.D. Tex Sept. 9, 2014).

<sup>54</sup>In re DePuy Orthopaedics, Inc., Pinnacle Hip Implant Products Liability Litig. , Case No. 3:11-md-02244-K, Doc. 120 (N.D. Tex. Sept. 3, 2014).

<sup>55</sup>In re DePuy Orthopaedics, Inc., Pinnacle Hip Implant Products Liability Litig. , Case No. 3:11-md-02244-K, Doc. 213 (N.D. Tex. Oct. 23, 2014).

<sup>56</sup>MDL Case Listing: In re DePuy Orthopaedics, Inc., Pinnacle Hip Implant Products Liability Litigation , 3:110md-0244 (available at <http://www.txnd.uscourts.gov/judges/MDL/depuy.html>).

<sup>57</sup>Id.

<sup>58</sup>Melkerson, M.N., Letter re 510(k) Approval for Smith & Nephew Reflection 3 (June 6, 2007) (available at [http://www.accessdata.fda.gov/cdrh\\_docs/pdf7/K070756.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf7/K070756.pdf)).

<sup>59</sup>Tillman D.B., Letter re PMA Approval for Smith & Nephew Birmingham Hip Resurfacing (BHR) System (May 9, 2006) (available at [http://www.accessdata.fda.gov/cdrh\\_docs/pdf4/p040033a.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf4/p040033a.pdf)).

<sup>60</sup>Supplemental PMA Approval for R3 Metal Liner Use with BHR System (Nov. 13, 2008) (available at <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=3986>); Supplemental PMA Approval for R3 Metal Liner Use with BHR System (Dec. 31, 2009) (available at <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=2>).

<sup>61</sup>Smith & Nephew, Inc. (June 1, 2012). Statement on Voluntary Withdrawal of R3 Metal Hip Component [Press Release] (available at <http://www.smith-nephew.com/news-and-media/news/voluntary-market-withdrawal-of-hip-component/>).

<sup>62</sup>Sun, L. (Nov. 13, 2013). How did this Company Lose Over \$6 Billion in Two Weeks? Motley Fool (available at <http://www.fool.com/investing/general/2013/11/13/how-did-this-company-lose-over-6-billion-in-2->

week.aspx).

<sup>63</sup> Smith & Nephew, Inc. (2013). 2013 Annual Financial Report (available at [http://www.smith-nephew.com/global/assets/pdf/corporate/smithnephew\\_annualreport\\_2013\\_complete.pdf](http://www.smith-nephew.com/global/assets/pdf/corporate/smithnephew_annualreport_2013_complete.pdf)).

<sup>64</sup> Haynes v. Smith & Nephew, Inc., Case No. CT-004783-12, Shelby County Cir. Ct., Div. 7, Order Granting Motion to Consolidate (July 11, 2013).

<sup>65</sup> Simon v. Smith & Nephew, Inc., Case No. 13-cv-1909-PAE (S.D. N.Y. Dec. 12, 2013); Bertini, et al. v. Smith & Nephew, Inc., Case No. 13-cv-79-BMC (E.D. N.Y. March 17, 2014).

<sup>66</sup> Melkerson, M.N., Letter re 510(k) Approval for Stryker Rejuvenate Modular Hip System (June 3, 2008) (available at [http://www.accessdata.fda.gov/cdrh\\_docs/pdf8/k081044.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf8/k081044.pdf)).

<sup>67</sup> Melkerson, M.N., Letter re 510(k) Approval for Stryker ABG II Modular Hip Stem (Nov. 4, 2009) (available at [http://www.accessdata.fda.gov/cdrh\\_docs/pdf9/k092406.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf9/k092406.pdf)).

<sup>68</sup> Stryker Orthopaedics (April 2012). Urgent Field Safety Notice RA-2012-067.

<sup>69</sup> Stryker Orthopaedics (June 1, 2012). Statement on Voluntary Recall of Rejuvenate and ABG II Modular Neck Stems [Press Release] (available at <http://www.fda.gov/safety/recalls/ucm311043.htm>).

<sup>70</sup>Id.

<sup>71</sup>In re Stryker Rejuvenate & ABG II Hip Implant Products Liability Litigation, Case MDL No. 2441, Doc. 170 (J.P.M.L. June 12, 2013) (<http://www.mnd.uscourts.gov/MDL-Stryker/index.shtml>).

<sup>72</sup>In re Stryker Rejuvenate & ABG II Modular Hip Stem Litigation, Case No. 296, Master Docket No. BER-L-936-13, Superior Ct. of New Jersey (Bergen County) (<http://www.judiciary.state.nj.us/mass-tort/abgstryker/index.htm>).

<sup>73</sup>In re Stryker Rejuvenate & ABG II Modular Hip Stem Litigation, Case No. 296, Master Docket No. BER-L-936-13, Superior Ct. of New Jersey (Bergen County), Case Management Order 18 (Aug. 4, 2014).

<sup>74</sup> A website for the Stryker settlement has been created. Documents and other information may be found at: <http://strykermodularhipsettlement.com/>

<sup>75</sup> A copy of the settlement agreement may be found at the Stryker settlement website: [http://strykermodularhipsettlement.com/docs/master\\_settlement\\_agreement.pdf](http://strykermodularhipsettlement.com/docs/master_settlement_agreement.pdf)

<sup>76</sup> Stryker Howmedica Osteonics Corp. Class II Device Recall of Accolade TMZF Stems (July 22, 2009). (available at [http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?start\\_search=1&event\\_id=50901](http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm?start_search=1&event_id=50901)).

<sup>77</sup> Lewis v. Stryker Orthopaedics, et al., Case No. 13-2196-DFW-FLN, Doc. 13 (D. Minn. Sept. 11, 2013).

<sup>78</sup>In re Wright Medical Technology, Inc., Conserve Hip Implant Products Liability Litigation, Case No. 1:12-md-02329-WSD, Doc. 1 (N.D. Ga. Feb. 27, 2012) ([http://www.gand.uscourts.gov/mdl/wright\\_medical.html](http://www.gand.uscourts.gov/mdl/wright_medical.html)).

<sup>79</sup>In re Wright Medical Technology, Inc., Conserve Hip Implant Products Liability Litigation, Case No. 1:12-md-

02329-WSD, Doc. 85 (N.D. Ga. May 22, 2012).

<sup>80</sup> Wright Hip Systems Cases, California JCCP 4710, Super. Ct. Cal. (Los Angeles County).

<sup>81</sup>Shimy, et al. v. Wright Medical Technology, Inc., et al., Case No. 14-4541-CAS, Doc. 17 (C.D. Cal. July 23, 2014).

<sup>82</sup>In re Wright Medical Technology, Inc., Conserve Hip Implant Products Liability Litigation, Case No. 1:12-md-02329-WSD, Doc. 1037 (Aug. 19, 2014).

<sup>83</sup> Witten, C.M., Letter re 510(k) Approval for Wright CONSERVE Plus Spiked Shell and Total 56mm Femoral Head (Oct. 31, 2013) (available at [http://www.accessdata.fda.gov/cdrh\\_docs/pdf3/k031963.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf3/k031963.pdf)).

<sup>84</sup> Witten, C.M., Letter re 510(k) Approval for Wright PROFEMUR S Hip Stem (July 9, 2004) (available at [http://www.accessdata.fda.gov/cdrh\\_docs/pdf3/P030042A.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf3/P030042A.pdf)).

<sup>85</sup> Tillman D.B., Letter re PMA Approval for Wright CONSERVE Plus Total Resurfacing Hip System (Nov. 3, 2009) (available at [http://www.accessdata.fda.gov/cdrh\\_docs/pdf3/P030042A.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf3/P030042A.pdf)).

<sup>86</sup> Sarvestani, A. (Nov. 1, 2012). Zimmer Pulls Metal-on-Metal Durom Acetabular Hip Implants from Australian Market. Hacking Humans (available at <http://arezusarvestani.wordpress.com/2012/11/01/zimmer-pulls-metal-on-metal-durom-acetabular-hip-implants-from-australian-market/>)

<sup>87</sup> Zimmer GmbH (Sept. 26, 2007). Product Recall Notification of the Durom Femoral Component 54 Code T and the Durom Femoral Component 46 Code L [Press Release] (available at <http://www.fda.gov/downloads/AboutFDA/CentersOffices/ORA/ORAElectronicReadingRoom/UCM161031.pdf>).

<sup>88</sup>Id.

<sup>89</sup>In re Zimmer Durom Hip Cup Products Liability Litigation, Case No. 2:09-cv-4414-SDW-MCA, Doc. 1 (D. N.J. June 6, 2010).

<sup>90</sup> Zimmer Holdings, Inc. (2013). 2013 Annual Financial Report (available at [http://files.shareholder.com/downloads/ZMH/3459316327xox737085/CA00C395-C704-48E2-B8BE-3314E28808C7/ZMH\\_2013\\_Annual\\_Report.pdf](http://files.shareholder.com/downloads/ZMH/3459316327xox737085/CA00C395-C704-48E2-B8BE-3314E28808C7/ZMH_2013_Annual_Report.pdf)).

<sup>91</sup>In re Zimmer Durom Hip Cup Products Liability Litigation, Case No. 2:09-cv-4414-SDW-MCA, Doc. 227 (D. N.J. Nov. 20, 2013).

<sup>92</sup> Cortez, M.F. (April 24, 2014). Zimmer to Buy Biomet for \$13.4 Billion Adding Orthopedics. Bloomberg (available at <http://www.bloomberg.com/news/2014-04-24/zimmer-agrees-to-buy-biomet-for-13-35-billion-including-debt.html>).

<sup>93</sup> A compendium of state-by-state statute of limitations for state products liability causes of action may be found at <https://attorney-group.com/blog/have-you-waited-too-long-to-file-a-hip-recall-claim/>

#### Author Bios

For more on this month's commentary authors, visit [Johnson & Vines, PLLC](#) or the [American Injury Attorney Group](#), a network of law firms that helps clients by associating them with qualified and experienced attorneys,



enhancing the legal team behind each case and giving clients confidence that their cases will be handled effectively.



Anthony C. Johnson is a managing partner attorney at Johnson & Vines, PLLC ([johnsonvines.com](http://johnsonvines.com)) and the CEO and co-founder of the American Injury Attorney Group ([attorney-group.com](http://attorney-group.com)). He received his BA at the University of Arkansas in Computer Engineering and his Juris Doctor from the University of Arkansas at Little Rock. His law practice started as a general practice but has since shifted towards mass torts, medical device litigation & other serious personal injury cases. Johnson's interests expand beyond the practice of law especially in the fields of business and technology. He was recently featured on the 2014 Empact Showcase of Top 100 entrepreneurs under 35 across the country. He is on The National Trial Lawyers 40 Under 40 list. He was listed by Arkansas Business as one of the "20 in their 20's" to look out for in 2012. He was also featured in the April 2012 cover story of the American Bar Association's Journal as one of "America's Techiest Lawyers."



Christopher D. Jennings is an attorney with Johnson Vines PLLC. His practice concentrates on complex litigation and representing consumers, businesses, and governmental entities in individual and class action antitrust, consumer protection, derivative, products liability, and federal securities cases. He has prosecuted numerous individual, mass tort, and class cases in state and federal courts throughout the nation. Most recently, Mr. Jennings's practice has focused extensively on assisting clients in pursuing claims related to defective metal-on-metal hip implants in both state and federal court. He has been named a Mid-South Super Lawyers Rising star in class action and mass tort litigation.

---

Copyright Note: This article was reproduced from the HarrisMartin Publishing Web site at [www.harrismartin.com](http://www.harrismartin.com). While dissemination of this article via e-mail, fax or regular mail -- provided it has not been altered in any fashion -- is permitted, dissemination of multiple articles through any medium is prohibited without express consent from HarrisMartin.

HarrisMartin Publishing - 30 Washington Avenue, Suite D-3, Haddonfield, NJ 08033  
(610) 647-5500 - [www.harrismartin.com](http://www.harrismartin.com) - [service@harrismartin.com](mailto:service@harrismartin.com)